Tacrolimus Versus Methotrexate as Rescue Therapy for Refractory Inflammatory Bowel Disease

Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, China

Status: Unknown

Conditions: Inflammatory Bowel Diseases

Study type: Observational

Funder types: Other

Identifiers

NCT03204136

shrjibdc20170401

Details and patient eligibility

About

Mesalazine, steroid, immunosuppressants and biologic agents are main medical treatments in treating inflammatory bowel diseases. Yet some patients develop severe side effects or initial invalid to conventional therapies. Some studies have already showed that tarcolimus and methotrexate are both effective in inducing and maintaining disease remission. Here we conduct a retrospective study to compare the efficancy of tarcolimus and methotrexate in treating refractory inflammatory bowel diseases as rescue therapy.

Enrollment: 60 estimated patients

Sex: All

Ages: 16 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Tarcolimus or methotrexate was used in refractory inflammatory bowel disease patents

Exclusion criteria

• Pregnant woman

Trial design

60 participants in 2 patient groups

tarcolimus

Description:

refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission

methotrexate

Description:

refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission